Anti-SARS-CoV-2 Envelope (NT)
| Code | Size | Price |
|---|
| LEI-S537-20ug | 20 ug | £199.00 |
Quantity:
| LEI-S537-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein. The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
Long Description:
A coronavirus, SARS-CoV-2, was first identified in 2019 (COVID-19). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS-CoV-2 can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
NCBI Gene:
43740570
Target:
SARS-CoV-2
References
1. Gorbalenya. bioRxiv: (2020).
2. Hui et al. Int J Infect Dis. (2020);91:264-266.
3. Pervushin et al. PLoS Pathog. (2009); 5(7): e1000511.
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV Envelope (CT) | LEI-S536 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe Acute Respiratory Syndrome E (CT) Blocking Peptide | LEI-S545 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome E (NT) Blocking Peptide | LEI-S546 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||